Zhao Xiaofeng, Huang Yinglin, Li Duolu, Han Chao, Kan Quancheng
aClinical Pharmacology Base, The First Affiliated Hospital of Zhengzhou University, Zhengzhou bDepartment of Psychiatry, Shengjing Hospital of China Medical University, Shenyang, People's Republic of China.
Psychiatr Genet. 2015 Feb;25(1):1-8. doi: 10.1097/YPG.0000000000000070.
Several studies have investigated the potential association between genetic polymorphisms of tryptophan hydroxylase 1 (TPH1) and antidepressant response. However, the results are inconsistent and inconclusive. Our aim was to assess the association of the TPH1 A218C polymorphism (rs1800532) with antidepressant response using ethnicity, antidepressant-specific, and ethnicity-antidepressant interactions in an updated meta-analysis.
Data were collected from the related literature published before December 2013 from MEDLINE and EMBASE databases. The meta-analysis was stratified by ethnicity, antidepressants, and ethnicity-antidepressant interaction, and was carried out using a random-effects model as appropriate using the Stata Statistical Package (version 11.0).
A total of 12 individual studies and the STARD study were identified in the current study, among which six studies and the STARD study (White part) reported on the TPH1 A218C polymorphism and antidepressant response in a White population, with 2035 cases, and six studies and the STARD study (Asian part) were carried out in an Asian population, with 707 cases. In terms of the classes of antidepressants, eight studies and the STARD study explored this relationship using selective serotonin reuptake inhibitors (SSRIs) and four studies used other/mixed antidepressants. We found that the TPH1 A218C genotype was not significantly associated with antidepressant response either in all populations or in White and Asian populations. Moreover, the results did not change according to an ethnicity-antidepressant interaction model either in White populations using SSRIs or other/mixed antidepressants or in Asian populations.
The TPH1 A218C polymorphism may not be associated with antidepressant response either in an ethnicity, antidepressant-specific population or in an ethnicity-antidepressant interaction model.
多项研究探讨了色氨酸羟化酶1（TPH1）基因多态性与抗抑郁反应之间的潜在关联。然而，结果并不一致且尚无定论。我们的目的是在一项更新的荟萃分析中，利用种族、抗抑郁药特异性以及种族 - 抗抑郁药相互作用来评估TPH1 A218C多态性（rs1800532）与抗抑郁反应的关联。
从MEDLINE和EMBASE数据库收集2013年12月之前发表的相关文献数据。荟萃分析按种族、抗抑郁药以及种族 - 抗抑郁药相互作用进行分层，并使用Stata统计软件包（版本11.0）酌情采用随机效应模型进行分析。
本研究共纳入12项个体研究和STARD研究，其中6项研究及STARD研究（白人部分）报告了白人人群中TPH1 A218C多态性与抗抑郁反应，共2035例；6项研究及STARD研究（亚洲部分）在亚洲人群中开展，共707例。就抗抑郁药类别而言，8项研究及STARD研究使用选择性5-羟色胺再摄取抑制剂（SSRI）探讨了这种关系，4项研究使用其他/混合抗抑郁药。我们发现，TPH1 A218C基因型在所有人群中，以及在白人和亚洲人群中，均与抗抑郁反应无显著关联。此外，无论是在使用SSRI或其他/混合抗抑郁药的白人人群中，还是在亚洲人群中，根据种族 - 抗抑郁药相互作用模型得出的结果均未改变。
TPH1 A218C多态性在种族、抗抑郁药特异性人群中，或在种族 - 抗抑郁药相互作用模型中，可能均与抗抑郁反应无关。
